Middle Molecule Find

Rulebook › V-tags › V127

V127 Antibody testing after hepatitis B vaccination

Written V0127 on the CMS-2567 and in QCOR.

Enforces CDC RR-05, adopted by reference at 42 CFR 494.30(a)(1)(i) · Appendix H Rev. 246, page 23 · checked 12 Nov 2026

Cited on this tag? What happens after a citation · One-page sheet for the binder

The regulation

CDC RR-05 Requirements as Adopted by Reference 42 CFR 494.30 (a)(1)(i)

Hepatitis B Screening: Patients and Staff

Test all vaccinees [patients and staff] for anti-HBs 1-2 months after last primary vaccine dose.

  • If anti-HBs is <10 mIU/mL, consider patient or staff member susceptible, revaccinate with an additional three doses, and retest for anti-HBs.
  • If anti-HBs are ≥10 mIU/mL, consider immune, and retest patients annually.
  • Give booster dose of vaccine to patients if anti-HBs declines to <10 mIU/mL and continue to retest patients annually.

CMS's interpretive guidance

Interpretive Guidance § 494.30(a)(1)(i)

According to the CDC, all patients and staff must be tested for anti-HBs 1–2 months after the last primary vaccine dose to determine their response to the vaccine. Patients and staff members who do not respond to the primary vaccine series should be revaccinated with a full course of vaccine and retested for response. No additional doses of vaccine are warranted for those who do not respond to the second series. Patients who require a booster dose of the HBV vaccine should not be assigned to a staff member concurrently caring for HBV+ positive patients.

The CDC defines an adequate response to vaccination as a laboratory result of ≥10 mIU/mL anti-HBs. The laboratory performing the testing for anti-HBs must be able to define a 10 mIU/mL concentration.

Results should be reported as a numeric value; a result of “positive” or “negative” is not sufficient. Some manufacturers of anti-HBs assays consider a level of anti-HBs slightly higher than 10mIU/mL to be protective. For these assays, the higher level of titer considered to be protective by the kit manufacturer should be used to determine whether or not the patient or staff member is immune.

Primary non-responders to vaccination who are HBsAg negative should be considered susceptible to HBV infection.

Patients who respond to the vaccine should be retested annually for anti-HBs. If anti-HBs declines to <10 mIU/mL, these patients should receive a booster dose of Hepatitis B vaccine and continue to be retested for anti-HBs annually. Retesting immediately after the booster dose is not necessary.

For staff members who initially respond to the vaccine, neither booster doses of vaccine nor periodic serologic testing to monitor antibody concentrations are necessary.

The facility and the responsible physicians should consult the CDC recommendations on dosing and revaccination.

Verbatim from Appendix H Rev. 246, with CMS's headings, lists and bold. Check page 23 (the full 469-page PDF) before quoting it.

Connected tags

Tags whose guidance points here

Questions on this site that cite it

Rulebook subjects that cite it